Institut Catala d'Oncologia de Girona- Hospital Universitari Dr Josep Trueta
- Address
- Av. de França s/n, 17007,, Girona, Spain
Institut Català d'Oncologia de Girona - Hospital Universitari Dr Josep Trueta
The Institut Català d'Oncologia de Girona, located at Hospital Universitari Dr Josep Trueta, is a specialized oncology research center dedicated to advancing cancer treatment through innovative clinical trials. The institution demonstrates particular expertise in thoracic oncology, focusing on precision medicine approaches for lung cancer patients with specific genetic mutations.
- Non-small cell lung cancer with EGFR mutations
- First-line targeted therapy research
- Advanced and metastatic lung cancer treatment
The center's research portfolio emphasizes molecular-driven therapeutics for lung cancer, particularly investigating novel treatments for patients harboring EGFR Exon 20 insertion mutations. Their participation in multi-center phase 3 trials evaluating targeted therapies versus traditional chemotherapy demonstrates their commitment to identifying optimal first-line treatment strategies for locally advanced or metastatic disease, ultimately contributing to improved outcomes for patients with molecularly defined lung cancer subtypes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Catala d'Oncologia de Girona- Hospital Universitari Dr Josep Trueta
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Study of Sunvozertinib vs. Platinum-Based Chemotherapy in EGFR Exon 20 Insertion Mutant Advanced NSCLC | Dizal Pharmaceutical Co. Ltd. | Phase III | Not Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 1 | Unknown | 2023-09-26 | 2023-09-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.